ABSTRACT

Background: Patient-reported quality of life in cancer patients is becoming increasingly important, especially for head-and-neck (H&N) cancers, which are at risk of experiencing severe treatment-related toxicities. Therefore, we sought to characterize the peritherapeutic HRQOL of contemporary patients using the well-validated EQ-5D-5 L questionnaire.

Methods: All patients receiving radiotherapy for H&N cancers between July 2019 and November 2019 at the University of Freiburg Medical Center who completed the first two follow-ups were included.

Results: All 49 patients completed the questionnaires at all time points of data collection, yielding 196 total questionnaires. The mean EQ-5D-5 L index score of the overall population before radiotherapy, after radiotherapy, and three and six months following radiotherapy was 0.837 (standard deviation, SD 0.17), 0.828 (SD 0.16), 0.855 (SD 0.15), and 0.856 (SD 0.14) respectively. The respective mean EQ VAS scores were 63.88 (SD 20.72), 63.67 (SD 21.81), 63.67 (SD 21.81), and 65.20 (SD 22.41) respectively. The respective changes of the HI and EQ VAS score over time for this cohort were not significant (Friedman test p = 0.273, p = 0.618).

Conclusion: Despite the known therapy-related toxicities, no significant permanent deterioration of HRQOL in this cohort was observed.

摘要

背景：患者报告的癌症患者生活质量变得越来越重要，尤其是对于头颈（H＆N）癌症而言，这种癌症有遭受严重的与治疗有关的毒性的风险。因此，我们试图使用经过充分验证的EQ-5D-5 L调查表来表征当代患者的治疗前后HRQOL。

方法：纳入所有在2019年7月至2019年11月期间在弗莱堡大学医学中心接受H＆N癌症放疗的患者，并完成了前两次随访。

结果：49例患者在数据收集的所有时间点都完成了问卷调查，总共获得196份问卷。放疗前，放疗后以及放疗后三个月和六个月总人群的平均EQ-5D-5 L指数得分为0.837（标准差，SD 0.17），0.828（SD 0.16），0.855（SD 0.15）和分别为0.856（SD 0.14）。分别的平均EQ VAS分数分别为63.88（SD 20.72），63.67（SD 21.81），63.67（SD 21.81）和65.20（SD 22.41）。该队列的HI和EQ VAS分数随时间的变化并不显着（Friedman检验p = 0.273，p = 0.618）。

结论：尽管已知与治疗有关的毒性，但在该队列中未观察到HRQOL的永久性显着恶化。